Advagraf + Prograf
ApprovedUNKNOWN 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Liver Transplantation
Conditions
Liver Transplantation
Trial Timeline
Nov 23, 2017 → Sep 30, 2025
NCT ID
NCT03216447About Advagraf + Prograf
Advagraf + Prograf is a approved stage product being developed by Astellas Pharma for Liver Transplantation. The current trial status is unknown. This product is registered under clinical trial identifier NCT03216447. Target conditions include Liver Transplantation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03216447 | Approved | UNKNOWN |
| NCT02251691 | Approved | UNKNOWN |
| NCT02268201 | Approved | Terminated |
| NCT01332201 | Phase 2 | Completed |
| NCT01742676 | Approved | Completed |
Competing Products
20 competing products in Liver Transplantation